In overexpression and CRISPR/Cas9 knockout experiments in prostate cancer cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice.
6630899 NAVWQNAI items 1 apa default asc 1
Haldrup, J., Strand, S. H., Cieza-Borrella, C., Jakobsson, M. E., Riedel, M., Norgaard, M., Hedensted, S., Dagnaes-Hansen, F., Ulhoi, B. P., Eeles, R., Borre, M., Olsen, J. V., Thomsen, M., Kote-Jarai, Z., & Sorensen, K. D. (2020). FRMD6 has tumor suppressor functions in prostate cancer. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01548-w Cite
Blue Earth Diagnostics’ manufacturing partner, Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
[Blue Earth Diagnostics]
6630899 nan items 1 apa default asc 1
The authors expand on the clinical development of PARP inhibitors (PARPis) in metastatic castration-resistant prostate cancer, discuss potential biomarkers that may predict successful tumor control, and summarize present and future clinical research on PARPis in the metastatic disease landscape.
Overexpression of regucalcin in bone metastatic human prostate cancer PC-3 and DU-145 cells suppressed colony formation and cell growth in vitro. Overexpressed regucalcin enhanced the levels of p53, Rb, and p21, and decreased the levels of Ras, PI3 kinase, Akt, and mitogen-activated protein kinase, leading to suppression of cell growth.
6630899 CGRBUX5Y items 1 apa default asc 1
Yamaguchi, M., Osuka, S., Murata, T., & Ramos, J. W. (2021). Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells. Translational Oncology, 14(1), 100955. https://doi.org/10.1016/j.tranon.2020.100955 Cite
Scientists demonstrated that inhibiting the P2X4 receptor impaired the growth and mobility of prostate cancer cells but not apoptosis. In BALB/c immunocompromised nude mice inoculated with human PC3 cells subcutaneously, 5-BDBD showed anti-tumourigenic effects.
6630899 9EIPAUT2 items 1 apa default asc 1
He, J., Zhou, Y., Arredondo Carrera, H. M., Sprules, A., Neagu, R., Zarkesh, S. A., Eaton, C., Luo, J., Gartland, A., & Wang, N. (2020). Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target. Cells, 9(11), 2511. https://doi.org/10.3390/cells9112511 Cite
Isogenic androgen-responsive and castration-resistant human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts.
6630899 DNHFPJ8J items 1 apa default asc 1
Malviya, G., Patel, R., Salji, M., Martinez, R. S., Repiscak, P., Mui, E., Champion, S., Mrowinska, A., Johnson, E., AlRasheedi, M., Pimlott, S., Lewis, D., & Leung, H. Y. (2020). 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research, 10(1), 143. https://doi.org/10.1186/s13550-020-00728-9 Cite
Investigators evaluated the potential effect of protein disulfide isomerase 4 on chemoresistance to docetaxel (DTX) in prostate cancer cells (DTX-resistant PC-3 cells and C4-2B cells) to investigate the underlying mechanisms.
In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of these polymer nanocarriers induced sufficient host T cells expressing tumor-specific CARs or virus-specific TCRs to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes.
6630899 VCTL57EA items 1 apa default asc 1
Investigators demonstrated that miR-199b-5p was significantly downregulated in metastatic prostate cancer (PCa) tissues and cells when compared with the normal prostate tissue, the localized disease, the weakly metastatic and androgen-dependent PCa cell and the normal prostate epithelial cell.
[British Journal of Cancer]
6630899 PP239EM6 items 1 apa default asc 1
Scientists indicated that upregulation of miR-211 has tumor-suppressive properties by inhibiting TGF-β pathway activation via INHBA in prostate cancer stem cells.
[Cancer Gene Therapy]
Researchers demonstrated an approach to identify cancer-driver coregulators in cancer, and that PGC1α expression is clinically significant yet underexplored coregulator in aggressive early stage prostate cancer.
6630899 SG6RH3H9 items 1 apa default asc 1
Identification of transcription factor co-regulators that drive prostate cancer progression | Scientific Reports. (n.d.). Retrieved November 24, 2020, from https://www.nature.com/articles/s41598-020-77055-5 Cite